These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7530176)

  • 1. Decay-accelerating factor protects human trophoblast from complement-mediated attack.
    Cunningham DS; Tichenor JR
    Clin Immunol Immunopathol; 1995 Feb; 74(2):156-61. PubMed ID: 7530176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses.
    Bergelson JM; Chan M; Solomon KR; St John NF; Lin H; Finberg RW
    Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6245-8. PubMed ID: 7517044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor.
    Pearce EJ; Hall BF; Sher A
    J Immunol; 1990 Apr; 144(7):2751-6. PubMed ID: 1690776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complement system in human reproduction.
    Vanderpuye OA; Labarrere CA; McIntyre JA
    Am J Reprod Immunol; 1992; 27(3-4):145-55. PubMed ID: 1384536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59.
    Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4195-202. PubMed ID: 11095615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation.
    Varsano S; Frolkis I; Rashkovsky L; Ophir D; Fishelson Z
    Am J Respir Cell Mol Biol; 1996 Dec; 15(6):731-7. PubMed ID: 8969267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
    Brodbeck WG; Mold C; Atkinson JP; Medof ME
    J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement.
    Marschang P; Sodroski J; Würzner R; Dierich MP
    Eur J Immunol; 1995 Jan; 25(1):285-90. PubMed ID: 7531147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decay accelerating factor (CD55).
    Nicholson-Weller A
    Curr Top Microbiol Immunol; 1992; 178():7-30. PubMed ID: 1385047
    [No Abstract]   [Full Text] [Related]  

  • 11. Structure and function of decay accelerating factor CD55.
    Nicholson-Weller A; Wang CE
    J Lab Clin Med; 1994 Apr; 123(4):485-91. PubMed ID: 7511675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition.
    Mason JC; Yarwood H; Sugars K; Morgan BP; Davies KA; Haskard DO
    Blood; 1999 Sep; 94(5):1673-82. PubMed ID: 10477692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor.
    Zaltzman AB; Van den Berg CW; Muzykantov VR; Morgan BP
    Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):651-6. PubMed ID: 7537958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A partial cDNA clone of trypomastigote decay-accelerating factor (T-DAF), a developmentally regulated complement inhibitor of Trypanosoma cruzi, has genetic and functional similarities to the human complement inhibitor DAF.
    Tambourgi DV; Kipnis TL; da Silva WD; Joiner KA; Sher A; Heath S; Hall BF; Ogden GB
    Infect Immun; 1993 Sep; 61(9):3656-63. PubMed ID: 7689538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55).
    Holmes CH; Simpson KL; Okada H; Okada N; Wainwright SD; Purcell DF; Houlihan JM
    Eur J Immunol; 1992 Jun; 22(6):1579-85. PubMed ID: 1376264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
    Matsumoto M; Sugita Y; Seya T
    Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
    Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
    J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of complement in humans with a first-trimester pregnancy loss.
    Tichenor JR; Bledsoe LB; Opsahl MS; Cunningham DS
    Gynecol Obstet Invest; 1995; 39(2):79-82. PubMed ID: 7737587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.